Clinic
Public Hospital District No 1 of Mason County
Public Hospital District No 1 of Mason County was paid $72.35M by Medicaid between Jan 2018 and Dec 2024, across 311 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoPUBLIC HOSPITAL DISTRICT NO 1 OF MASON COUNTY
SHELTON, WA 98584
SHELTON, WA 98584
33aNPI1760568752assigned 10/31/2006
33bProvider typeClinic/Center
28Total paid$72.35M
24GClaims816,009
24DCodes billed311
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Washington
Rank by total paid#1 of 113
Median peer was paid$110K
This provider vs. median660×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MOLL, ERIC controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 114,719 | $9.13M | |
| 2019 | 123,007 | $9.69M | |
| 2020 | 108,796 | $9.00M | |
| 2021 | 113,689 | $8.48M | |
| 2022 | 125,664 | $13.07M | |
| 2023 | 130,664 | $13.12M | |
| 2024incomplete | 99,470 | $9.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 39,027 | 34,685 | $8.75M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 45,518 | 42,017 | $8.62M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 12,322 | 9,342 | $6.57M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 3,704 | 3,521 | $4.91M |
| G0378 | Hospital observation service, per hour | 6.3% | 5,208 | 2,609 | $4.55M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 14,386 | 13,599 | $1.97M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 3,633 | 3,429 | $1.90M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 1,752 | 1,697 | $1.83M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.0% | 14,016 | 6,275 | $1.48M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 21,252 | 7,840 | $1.20M |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 59,532 | 49,387 | $1.08M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 6,897 | 6,007 | $1.06M |
299 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 9,231 | $1.03M |
| 80053 | Comprehensive metabolic panel | 1.1% | 25,920 | $826K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 727 | $803K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 4,442 | $728K |
| 59025 | Fetal non-stress test | 1.0% | 2,366 | $726K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,860 | $716K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,652 | $639K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 459 | $604K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,802 | $593K |
| 80050 | General health panel | <1% | 4,522 | $584K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,388 | $561K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,172 | $521K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,840 | $469K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,672 | $467K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 713 | $466K |
| 83690 | <1% | 6,354 | $439K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,784 | $424K |
| 84484 | <1% | 7,300 | $422K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,371 | $421K |
| 73630 | <1% | 2,966 | $410K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,015 | $399K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,561 | $394K |
| 73030 | <1% | 2,493 | $381K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,482 | $380K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,740 | $367K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,912 | $353K |
| 80061 | Lipid panel | <1% | 10,367 | $346K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,813 | $346K |
| 73130 | <1% | 2,054 | $333K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,427 | $332K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,471 | $329K |
| 73610 | <1% | 2,164 | $318K | |
| 76801 | <1% | 1,414 | $317K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,268 | $314K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,565 | $302K |
| 81001 | <1% | 11,097 | $300K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,271 | $295K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,141 | $277K |
| 73110 | <1% | 1,717 | $276K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,004 | $275K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,823 | $272K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,162 | $264K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,689 | $241K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,316 | $233K |
| 86850 | <1% | 4,257 | $219K | |
| 97161 | <1% | 3,907 | $218K | |
| 73560 | <1% | 1,690 | $210K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 222 | $200K |
| 72100 | <1% | 1,487 | $181K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,049 | $179K |
| 87081 | <1% | 5,170 | $163K | |
| 87070 | <1% | 3,763 | $161K | |
| 73562 | <1% | 979 | $160K | |
| 84702 | <1% | 3,170 | $160K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,384 | $158K |
| 87186 | <1% | 5,483 | $157K | |
| 86803 | <1% | 4,231 | $152K | |
| 83605 | <1% | 3,850 | $146K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,535 | $143K |
| 97533 | <1% | 1,649 | $124K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,801 | $123K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,953 | $120K |
| 87040 | <1% | 2,467 | $120K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,503 | $117K |
| 83880 | <1% | 2,497 | $114K | |
| 73502 | <1% | 951 | $110K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 116 | $109K |
| 97162 | <1% | 1,366 | $103K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,107 | $103K |
| 86901 | <1% | 3,903 | $101K | |
| 86900 | <1% | 3,852 | $99K | |
| 86140 | <1% | 3,361 | $98K | |
| 85610 | <1% | 7,415 | $93K | |
| 73565 | <1% | 631 | $93K | |
| 86780 | <1% | 3,404 | $90K | |
| 82728 | <1% | 2,319 | $90K | |
| 85379 | <1% | 1,492 | $89K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,901 | $88K |
| 81025 | <1% | 4,668 | $86K | |
| 93971 | <1% | 295 | $84K | |
| 84439 | <1% | 2,357 | $82K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,240 | $80K |
| 87481 | <1% | 2,571 | $80K | |
| 87077 | <1% | 3,765 | $80K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,313 | $79K |
| 87147 | <1% | 3,988 | $76K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,042 | $76K |
| 96376 | <1% | 1,239 | $74K | |
| 82607 | <1% | 2,236 | $74K | |
| 85027 | <1% | 3,047 | $74K | |
| 76942 | <1% | 228 | $73K | |
| 83735 | <1% | 3,773 | $72K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,760 | $71K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,098 | $71K |
| 82948 | <1% | 5,729 | $69K | |
| 84703 | <1% | 1,633 | $69K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 532 | $69K |
| 87340 | <1% | 3,111 | $68K | |
| 64450 | <1% | 136 | $67K | |
| 84145 | <1% | 1,572 | $66K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 209 | $65K |
| 87205 | <1% | 2,751 | $62K | |
| 82803 | <1% | 1,379 | $62K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 548 | $59K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,208 | $57K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,172 | $56K |
| 70498 | <1% | 50 | $55K | |
| 12001 | <1% | 273 | $52K | |
| 83540 | <1% | 1,936 | $50K | |
| 87480 | <1% | 2,046 | $49K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 278 | $49K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 642 | $48K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,955 | $46K |
| 87510 | <1% | 1,957 | $46K | |
| 81003 | <1% | 4,575 | $44K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,130 | $43K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 234 | $43K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,327 | $43K |
| 97165 | <1% | 470 | $42K | |
| 87660 | <1% | 1,670 | $41K | |
| 87185 | <1% | 2,271 | $41K | |
| 73140 | <1% | 353 | $40K | |
| J3490 | Unclassified drugs | <1% | 5,893 | $40K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 678 | $40K |
| 82043 | <1% | 1,601 | $40K | |
| 87420 | <1% | 470 | $38K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 513 | $38K |
| 72040 | <1% | 242 | $36K | |
| 86762 | <1% | 1,881 | $36K | |
| 82570 | <1% | 2,204 | $35K | |
| 82746 | <1% | 913 | $34K | |
| 82105 | <1% | 1,022 | $34K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,562 | $34K |
| 97597 | <1% | 236 | $32K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,652 | $32K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,103 | $32K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 555 | $31K |
| 82950 | <1% | 1,542 | $29K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,023 | $29K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 38 | $28K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 56 | $28K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,197 | $28K |
| 83550 | <1% | 1,527 | $27K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,658 | $27K |
| 80076 | <1% | 1,271 | $27K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 125 | $25K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 386 | $25K |
| 74018 | <1% | 182 | $24K | |
| 90715 | <1% | 762 | $24K | |
| 99442 | <1% | 515 | $22K | |
| 85652 | <1% | 1,306 | $22K | |
| 71250 | <1% | 44 | $22K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 954 | $22K |
| 86336 | <1% | 378 | $22K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,488 | $22K |
| 84403 | <1% | 607 | $21K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,178 | $19K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,528 | $18K |
| 76000 | <1% | 134 | $17K | |
| 85651 | <1% | 1,148 | $17K | |
| 84100 | <1% | 854 | $17K | |
| 73564 | <1% | 87 | $16K | |
| 82677 | <1% | 366 | $16K | |
| 76770 | <1% | 65 | $16K | |
| 94761 | <1% | 677 | $16K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,214 | $16K |
| 85730 | <1% | 600 | $16K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,155 | $15K |
| 76642 | <1% | 86 | $15K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,072 | $15K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,587 | $15K |
| 82550 | <1% | 494 | $14K | |
| 71100 | <1% | 78 | $13K | |
| 10060 | <1% | 96 | $12K | |
| 36416 | <1% | 3,056 | $12K | |
| 84153 | <1% | 328 | $11K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,451 | $11K |
| 86701 | <1% | 390 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,366 | $10K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,127 | $10K |
| 86703 | <1% | 406 | $9K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 999 | $9K |
| 72084 | <1% | 34 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $9K |
| 86038 | <1% | 346 | $8K | |
| 74019 | <1% | 50 | $8K | |
| 84156 | <1% | 342 | $8K | |
| 76536 | <1% | 37 | $8K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,650 | $8K |
| 86258 | <1% | 134 | $8K | |
| 84146 | <1% | 261 | $7K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 673 | $6K |
| 87522 | Neg quan hep c or qual rna | <1% | 43 | $6K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 14 | $6K |
| 86706 | <1% | 227 | $6K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,215 | $6K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,263 | $6K |
| 81513 | <1% | 1,423 | $5K | |
| 94060 | <1% | 17 | $5K | |
| 70486 | <1% | 12 | $5K | |
| 51702 | <1% | 92 | $4K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 161 | $4K |
| 86704 | <1% | 149 | $4K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 219 | $4K |
| 87088 | <1% | 163 | $4K | |
| 73590 | <1% | 25 | $4K | |
| 76882 | <1% | 14 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 24 | $3K |
| 84550 | <1% | 400 | $3K | |
| 73080 | <1% | 28 | $3K | |
| 82553 | <1% | 73 | $3K | |
| 76775 | <1% | 12 | $3K | |
| 76870 | <1% | 12 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 218 | $3K |
| 86431 | <1% | 133 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 13 | $2K |
| 81002 | <1% | 1,098 | $2K | |
| 73090 | <1% | 21 | $2K | |
| 86364 | <1% | 34 | $2K | |
| 72082 | <1% | 12 | $2K | |
| 83970 | <1% | 15 | $2K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 22 | $2K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 215 | $2K |
| 88720 | <1% | 314 | $2K | |
| 87046 | <1% | 42 | $2K | |
| 86922 | <1% | 19 | $2K | |
| 82009 | <1% | 258 | $2K | |
| 87045 | <1% | 66 | $2K | |
| 97163 | <1% | 15 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 107 | $1K |
| 87899 | <1% | 74 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,595 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 235 | $1K |
| 0003A | <1% | 50 | $1K | |
| 83615 | <1% | 46 | $1K | |
| 82565 | <1% | 77 | $1K | |
| 73070 | <1% | 14 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $1K |
| 85014 | <1% | 73 | $1K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,363 | $1K |
| 96367 | <1% | 12 | $978.33 | |
| 83516 | <1% | 15 | $950.15 | |
| 86708 | <1% | 41 | $950.05 | |
| 83001 | <1% | 34 | $924.60 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 26 | $887.65 |
| 82140 | <1% | 12 | $865.48 | |
| 87075 | <1% | 28 | $842.58 | |
| 82951 | <1% | 12 | $834.88 | |
| 82784 | <1% | 28 | $814.44 | |
| 85018 | <1% | 49 | $785.70 | |
| 83002 | <1% | 32 | $782.55 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 165 | $764.47 |
| 87427 | <1% | 27 | $734.29 | |
| 90686 | <1% | 26 | $577.39 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 29 | $541.52 |
| 92134 | <1% | 176 | $529.74 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 63 | $484.13 |
| 86480 | <1% | 12 | $464.50 | |
| 0002A | <1% | 20 | $460.53 | |
| A4565 | Slings | <1% | 81 | $457.15 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 35 | $410.82 |
| 87015 | <1% | 26 | $391.07 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $363.66 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 34 | $353.87 |
| 82247 | <1% | 15 | $340.38 | |
| 83655 | <1% | 12 | $336.85 | |
| 0013A | <1% | 15 | $321.51 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 27 | $321.01 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 23 | $293.34 |
| 86707 | <1% | 12 | $278.69 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,257 | $268.05 |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 82 | $260.29 |
| A9270 | Non-covered item or service | <1% | 25,932 | $260.25 |
| 82952 | <1% | 12 | $249.63 | |
| 82977 | <1% | 14 | $245.56 | |
| 84132 | <1% | 13 | $162.60 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 34 | $144.96 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 20 | $144.29 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 12 | $139.04 |
| 82947 | <1% | 12 | $121.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 30 | $70.13 |
| 81015 | <1% | 53 | $40.34 | |
| 80349 | <1% | 38 | $25.94 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 57 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 221 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 136 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 174 | $0.00 |
| 99217 | 0% | 54 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| G9162 | Spoken language expression functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 29 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 424 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 359 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 916 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 1,103 | $0.00 |
| 99225 | 0% | 37 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 43 | $0.00 |
| G9163 | Spoken language expression functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| 99219 | 0% | 15 | $0.00 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOLL, ERIC (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Public Hospital District No 1 of Mason County | Shelton, WA | $35.56M |
| Public Hospital District No 1 of Mason County | Shelton, WA | $3.89M |
| Public Hospital District No 1 of Mason County | Shelton, WA | $3.81M |
| Public Hospital District No 1 of Mason County | Shelton, WA | $1.64M |
| Public Hospital District No 1 of Mason County | Shelton, WA | $1.20M |
| Public Hospital District No 1 of Mason County | Hoodsport, WA | $925K |
| Public Hospital District No 1 of Mason County | Shelton, WA | $491K |
| Public Hospital District No 1 of Mason County | Shelton, WA | $23K |
| Public Hospital District No 1 of Mason County Wa | Shelton, WA | $17K |
| Public Hopsital District No 1 of Mason County | Shelton, WA | $16K |
| Public Hospital District No 1 of Mason County | Shelton, WA | $862.22 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.